P63in epithelial survival, germ cell surveillance, and neoplasia

Annual Review of Pathology: Mechanisms of Disease

Volumn 5, Issue , 2010, Pages 349-371

  Crum, Christopher P ^a   McKeon, Frank D ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Development; Squamous epithelium; Stem cells; Thymus

Indexed keywords

PROTEIN P63; PHOSPHOPROTEIN; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRP63 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

BREAST; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POPULATION; CELL SURVIVAL; GENE MUTATION; GENITAL SYSTEM; GENOME ANALYSIS; GERM CELL; IMMUNOHISTOCHEMISTRY; NEOPLASM; NONHUMAN; OVARY CELL; PHYLOGENY; PLACENTA; PRIORITY JOURNAL; PROSTATE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; UROGENITAL SYSTEM; UTERINE CERVIX; ANIMAL; EPITHELIUM CELL; HUMAN; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STEM CELL;

ANIMALS; CELL SURVIVAL; EPITHELIAL CELLS; GERM CELLS; HUMANS; MICE; NEOPLASMS; PHOSPHOPROTEINS; STEM CELLS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 77949894769     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-121808-102117     Document Type: Review

References (64)

1. Levine AJ, Hu W, Feng Z. 2006. The p53 pathway: What questions remain to be explored? Cell Death Differ. 13:1027-1036
2. Scheffner M,Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136
3. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, et al. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2:305-316
4. Melino G, De Laurenzi V, Vousden KH. 2002. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer 2:605-615
5. Melino G, Lu X, Gasco M, Crook T, Knight RA. 2003. Functional regulation of p63 and p73:development and cancer. Trends Biochem. Sci. 28:663-670
6. Mills AA, Zheng B,Wang XJ, Vogel H, Roop DR, Bradley A. 1999. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708-713
7. Yang A, Schweitzer R, Sun D, Kaghad M,Walker N, et al. 1999. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714-718
8. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, et al. 2000. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99-103
9. Senoo M, Pinto F, Crum CP, McKeon F. 2007. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129:523-536
10. Quade BJ, Yang A, Wang Y, Sun D, Park JJ, et al. 2001. Expression of the p53 homologue p63 in early cervical neoplasia. Gynecol. Oncol. 80:24-29
11. Mills AA. 2006. p63: oncogene or tumor suppressor? Curr. Opin. Genet. Dev. 16:38-44
12. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, et al. 2006. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol. Cell 24(4):593-602
13. Lo Coco F, Ye BH, Lista F, Corradini P, Offit K, et al. 1994. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 83:1757-1759 (Pubitemid 24107897)
14. Heselmeyer K, Schrock E, du Manoir S, Blegen H, Shah K, et al. 1996. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc. Natl. Acad. Sci. USA 93:479-484
15. Ince TA, Cviko AP, Quade BJ, Yang A, McKeon FD, et al. 2002. p63 coordinates anogenital modeling and epithelial cell differentiation in the developing female urogenital tract. Am. J. Pathol. 161(4):1111-1117
16. Innis JW,Mortlock DP. 1999. Limb development: molecular dysmorphology at hand! Clin. Genet. 53:337-348
17. Richardson MK, Carl TF, Hanken J, Elinson RP, Cope C, Bagley P. 1998. Limb development and evolution: a frog embryo with no apical ectodermal ridge (AER). J. Anat. 192(Part 3):379-390
18. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, et al. 2006. p63 protects the female germ line during meiotic arrest. Nature 444:624-628
19. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, et al. 2000. p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 157:1769-1775
20. Kurita T, Cunha GR. 2001. Roles of p63 in differentiation of M̈ullerian duct epithelial cells. Ann. N. Y. Acad. Sci. 948:9-12
21. Kurita T, Mills AA, Cunha GR. 2004. Roles of p63 in the diethylstilbestrol-induced cervicovaginal adenosis. Development 131:1639-1649
22. Rinne T, Brunner HG, van Bokhoven H. p63 associated disorders. Cell Cycle 6:262-268
23. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, et al. 1999. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99:143-153
24. van Bokhoven H, Brunner HG. 2002. Splitting p63. Am. J. Hum. Genet. 71:1-13
25. van Bokhoven H, JungM,Smits AP, van Beersum S, Ruschendorf F, et al. 1999. Limbmammarysyndrome: A new genetic disorder with mammary hypoplasia, ectrodactyly, and other hand/foot anomalies maps to human chromosome 3q27. Am. J. Hum. Genet. 64:538-546
26. Propping P, Zerres K. 1993. ADULT syndrome: an autosomal-dominant disorder with pigment anomalies, ectrodactyly, nail dysplasia, and hypodontia. Am. J. Med. Genet. 45:642-648
27. Hay RJ,Wells RS. 1976. The syndrome of ankyloblepharon, ectodermal defects and cleft lip and palate: an autosomal dominant condition. Br. J. Dermatol. 94:277-289
28. Rapp RS, Hodgkin WE. 1968. Anhidrotic ectodermal dysplasia: autosomal dominant inheritance with palate and lip anomalies. J. Med. Genet. 5:269-272
29. Kantaputra PN,Hamada T, Kumchai T, McGrath JA. 2003. Heterozygous mutation in the SAM domain of p63 underlies Rapp-Hodgkin ectodermal dysplasia. J. Dent. Res. 82:433-437
30. Watt FM. 2001. Stem cell fate and patterning in mammalian epidermis. Curr. Opin. Genet. Dev. 11:410-417
31. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. 2004. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 18:126-131
32. Gordon J, Wilson VA, Blair NF, Sheridan J, Farley A, et al. 2004. Functional evidence for a single endodermal origin for the thymic epithelium. Nat. Immunol. 5:546-553
33. Bleul CC, Corbeaux T, Reuter A, Fisch P, Monting JS, Boehm T. 2006. Formation of a functional thymus initiated by a postnatal epithelial progenitor cell. Nature 441:992-996
34. Rossi SW, Jenkinson WE, Anderson G, Jenkinson EJ. 2006. Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium. Nature 441:988-991
35. Sugimura Y, Cunha GR, Donjacour AA. 1986. Morphogenesis of ductal networks in the mouse prostate. Biol. Reprod. 34:961-971
36. Timms BG, Mohs TJ, Didio LJ. 1994. Ductal budding and branching patterns in the developing prostate. J. Urol. 151:1427-1432
37. Roy-Burman P,Wu H, Powell WC, Hagenkord J, Cohen MB. 2004. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr. Relat. Cancer 11:225-254
38. Ware JL. 1994. Prostate cancer progression. Implications of histopathology. Am. J. Pathol. 145:983-993
39. Witkiewicz AK, Hecht JL, Cviko A, McKeon FD, Ince TA, Crum CP. 2005. Croglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells. Hum. Pathol. 36:154-161
40. Greeley C, Schroeder S, Silverberg SG. 1995. Microglandular hyperplasia of the cervix: a true "pill" lesion? Int. J. Gynecol. Pathol. 14:50-54
41. O'Connell JT, Mutter GL, Cviko A, Nucci M, Quade BJ, et al. 2001. Identification of a "reserve cell" immunophenotype in benign and neoplastic endometrium: a study with the p53 homologue p63. Gynecol. Oncol. 80:30-36
42. Hamada T, Kiyokawa T, Nomura K, Hano H. 2008. Immunohistochemical analysis of reserve cell-like cells of ovarianMullerian mucinous/mixed epithelial borderline tumor. Int. J. Gynecol. Pathol. 27:199-206
43. Shih IM, Kurman RJ. 2004. p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am. J. Surg. Pathol. 28:1177-1183
44. Lee Y, Kim KR, McKeon F, Yang A, Boyd TK, et al. 2007. A unifying concept of trophoblastic differentiation and malignancy defined by biomarker expression. Hum. Pathol. 38:1003-1013
45. Peters H. 1970. Migration of gonocytes into the mammalian gonad and their differentiation. Phil. Trans. R. Soc. Lond. B 259:91-101
46. Lane DP. 1992. Cancer: p53, guardian of the genome. Nature 538:15-16
47. Lee H, Kimelman D. 2002. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev. Cell 2:607-616
48. Aberdam D, Gambaro K, Rostagno P, Aberdam E, de la Forest-Divonne S, Rouleau M. 2007. Key role of p63 in BMP-4-induced epidermal commitment of embryonic stem cells. Cell Cycle 6:291-294
49. Medawar A, Virolle T, Rostagno P, de la Forest-Divonne S, Gambaro K, et al. 2008. Np63 is essential for epidermal commitment of embryonic stem cells. PLoS ONE 3(10):e3441
50. Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA. 2006. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev. 20:3185-3197
51. Mikkola ML. 2007. p63 in skin appendage development. Cell Cycle 6:285-290
52. Gu X, Lundqvist EN, Coates PJ, Thurfjell N,Wettersand E, Nylander K. 2006. Dysregulation of TAp63 mRNA and protein levels in psoriasis. J. Investig. Dermatol. 126:137-141
53. Barbareschi M, Pecciarini L, Cangi MG,Macr̀ E, Rizzo A, et al. 2001. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am. J. Surg. Pathol. 25:1054-1060
54. Ali TZ, Epstein JI. 2008. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am. J. Surg. Pathol. 32:1890-1895
55. Wang TY, Chen BF, Yang YC, Chen H,Wang Y, et al. 2001. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum. Pathol. 32:479-486
56. Wu M, Wang B, Gil J, Sabo E, Miller L, et al. 2003. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing smallcell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am. J. Clin. Pathol. 119:696-702
57. Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, et al. 2007. TAp63 and -Np63 in cancer and epidermal development. Cell Cycle 6:274-285
58. Brandsma JL, Abramson AL. 1989. Association of papillomavirus with cancers of the head and neck. Arch. Otolaryngol. Head Neck Surg. 115:621-625
59. Riethdorf S, Neffen EF, Cviko A, L̈oning T, Crum CP, Riethdorf L. 2004. p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias. Hum. Pathol. 35:1477-1483
60. M̈unger K, Howley PM. 2002. Human papillomavirus immortalization and transformation functions. Virus Res. 89:213-228
61. Cui R, He J, Mei R, de Fromentel CC, Martel-Planche G, et al. 2005. Expression of p53, p63, and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus. Biochem. Biophys. Res. Commun. 336:339-345
62. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, et al. 2003. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin. Cancer Res. 9:5501-5507
63. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, et al. 2002. Loss of p63 expression is associated with tumor progression in bladder cancer. Am. J. Pathol. 161:1199-1206
64. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, et al. 2006. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc. Natl. Acad. Sci. USA 103:8435-8440